



SIXTEENTH ANNUAL

Report and Survey of Biopharmaceutical Manufacturing Capacity and Production



*A Study of Biotherapeutic
Developers and
Contract
Manufacturing
Organizations*



INSTITUTION PARTNERS



MEDIA PARTNERS



SIXTEENTH ANNUAL

Report and Survey of Biopharmaceutical Manufacturing Capacity and Production

*A Study of Biotherapeutic Developers and Contract
Manufacturing Organizations*

April 2019



BioPlan Associates, Inc.
2275 Research Blvd., Suite 500
Rockville, MD 20850 USA
301.921.5979
www.bioplanassociates.com

Copyright ©2019 by BioPlan Associates, Inc.

All rights reserved. Unauthorized reproduction strictly prohibited.

16th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production

*A Study of Biotherapeutic Developers and Contract
Manufacturing Organizations*

April 2019

BioPlan Associates, Inc.
2275 Research Blvd, Suite 500
Rockville MD 20850
301-921-5979
www.bioplanassociates.com

Copyright © 2019 by BioPlan Associates, Inc.

All rights reserved, including the right of reproduction in whole or in part in any form. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the written permission of the publisher.

For information on special discounts or permissions contact
BioPlan Associates, Inc. at 301-921-5979, or info@bioplanassociates.com

Managing Editor: Donnie E. Gillespie
Senior Contributor and Reviewer: Ronald A. Rader
Assistant Editors: Alla Rutstein Bobbitt, Ilene Roizman
Layout and Cover Design: ES Design

ISBN 978-1-934106-36-5

ACKNOWLEDGMENT

We wish to acknowledge the contributions of our authors and **Subject Matter Experts**. Without their thorough analysis of the data, this project would not have been possible:

- Patrick Evrard, Senior Principal Engineer Single -Use Technologies, Technical Communication and Regulatory Strategy, Pall Biotech
- Paul Spencer, Owner, PharmaMercenary
- Stefan Schmidt, COO/Head of Operations, BioAtrium AG
- Christoph Winterhalter, Senior Vice President, Business Development, AGC Biologics

We would also like to recognize our **Institution Partners**, and our Media Sponsors. Their efforts in assuring the cooperation and participation in the survey of their respective memberships helped guarantee the large group of survey participants to ensure data accuracy.

Our Institution Partners, all of whom contributed their time and effort to ensure the broad, international coverage of this project, include:

- AusBiotech (Malvern, Victoria, Australia)
- BIO (Biotechnology Industry Organization, Washington, D.C.)
- BioMaryland (Baltimore, MD)
- Bio-Process Systems Alliances/SOCMA (BPSA) (Washington, D.C.)
- bioLIVE, adjacent to CPhI Worldwide (Madrid, Spain)
- BioMaryland (Rockville, MD)
- Bio-Process Systems Alliance (BPSA) (Arlington, VA)
- California Life Sciences Association (CLSA) (San Francisco, CA)
- D2L Pharma (Bangalore, India)
- North Carolina BioSciences Organization (Research Triangle Park, NC)
- North Carolina Biotechnology Center (Research Triangle Park, NC)
- Pharma & Biopharma Outsourcing Association (PBOA) (Ringwood, NJ)

To ensure global coverage for this project, we again invited major **Media Sponsors** to support our outreach to biopharmaceutical decision-makers. Our media sponsors, who helped ensure broad and representative coverage of industry participation, include:

- American Pharmaceutical Review (South San Francisco, CA)
- BioPharm International (Iselin, NJ)
- BioProcess International (Westborough, MA)
- BioProcess Online (Eric, PA)
- Contract Pharma (Ramsey, NJ)
- Pharmaceutical Manufacturing (Schaumburg, IL)
- Pharmaceutical Technology (Iselin, NJ)
- Pharmaceutical Technology Europe (Iselin, NJ)

The early participation of our authors and sponsors in evaluating the areas and trends to be surveyed this year ensured the project was designed to cover the most relevant issues in biopharmaceutical manufacturing today. As always, their continued support was critical to the success of the project.

Eric S. Langer
Editor

ABOUT BIOPLAN ASSOCIATES, INC.

BioPlan Associates, Inc. is a biotechnology and life sciences market analysis, research, and publishing organization. We have managed biotechnology, biopharmaceutical, diagnostic, and life sciences research projects for companies of all sizes for almost 30 years. Our extensive market analysis, research and management project experience covers biotechnology and biopharmaceutical manufacturing, vaccine and therapeutic development, contract research services, diagnostics, devices, biotechnology supply, physician office labs and hospital laboratory environments.

We prepare custom studies, and provide public information our clients require to make informed strategic decisions, define objectives, and identify customer needs. With market information, our clients are better able to make informed, market-based decisions because they understand the trends and needs in high technology industries.

BioPlan Associates, Inc.
2275 Research Blvd., Suite 500
Rockville, MD 20850 USA
www.bioplanassociates.com
Tel: 301-921-5979

ABOUT THE AUTHORS: (ALPHABETICAL)

Patrick Evrard, Senior Principal Engineer Single-Use Technologies, Technical Communication and Regulatory Strategy

Patrick Evrard joined Pall Biotech in 2017, as Senior Director, SLS Single-Use Technologies, to manage the technical team providing expert technical support to Pall Biotech's customers. Before joining Pall, he led for more than 10 years a global technical team in charge of developing and implementing single-use technologies in GSK Vaccines' commercial manufacturing operations. Patrick and his team implemented at global level single-use technologies in critical sterile applications and re-engineered several vaccines processes, switching from classical grade A open processes to closed systems. Mr. Evrard has written and contributed to several articles and white papers on single-use technologies, was part of the Board of Directors of the Bio-Process Systems Alliance (BPSA). He has been participating since 2012 in several single-use technology industry work groups, from BPSA, BioPhorum Operations Group (BPOG), American Society of Mechanical Engineers (ASME BPE) and ASTM International.

Stefan R. Schmidt, COO/Head of Operations, BioAtrium AG

Dr. Stefan R. Schmidt currently serves as COO/Head of Operations at BioAtrium AG, a Lonza and Sanofi JV in Switzerland. Previously he held the position as CSO and other senior executive roles at Rentschler Biopharma with overall responsibilities for development, production and innovation. Before that, he was CSO at ERA Biotech in Barcelona, directing the company's R&D efforts. Prior to that, he worked at AstraZeneca in Sweden where he led the unit of Protein Sciences as Associate Director. He started his leadership career in Munich more than 20 years ago where he built up protein biochemistry teams for Connex and GPC-Biotech. During his academic education he earned a PhD in Biochemistry and an MBA in Marketing.

Paul Spencer, Owner, PharmaMercenary

Paul Spencer has a BS in Chemical Engineering, an MBA, and is a licensed PE in two states. Mr. Spencer started his career in the fermentation and purification of Monoclonal Antibody based diagnostic products. This included work conjugating MAbs to diagnostic markers. Later work has involved research to commercial manufacturing of innovative therapies, as well as high volume/high complete products. Mr. Spencer has 35 years of technical experience in a many of the therapeutic facilities. He provides a highly technical capability to those pharmaceutical units due to his 35 years of experience. He is a person that has been involved in significant improvements to the marketplace, often considered a thought leader in multiple unit operations and technological developments.

Christoph Winterhalter, Senior Vice President, Business Development, AGC Biologics

Dr. Christoph Winterhalter has 24 years of experience in Life Science and serves currently as Senior Vice President Business Development at AGC Biologics, a global biopharmaceutical CDMO with sites in US, EU and Japan. Before that he was heading

ABOUT THE AUTHORS: (ALPHABETICAL)

Patrick Evrard, Senior Principal Engineer Single-Use Technologies, Technical Communication and Regulatory Strategy

Patrick Evrard joined Pall Biotech in 2017, as Senior Director, SLS Single-Use Technologies, to manage the technical team providing expert technical support to Pall Biotech's customers. Before joining Pall, he led for more than 10 years a global technical team in charge of developing and implementing single-use technologies in GSK Vaccines' commercial manufacturing operations. Patrick and his team implemented at global level single-use technologies in critical sterile applications and re-engineered several vaccines processes, switching from classical grade A open processes to closed systems. Mr. Evrard has written and contributed to several articles and white papers on single-use technologies, was part of the Board of Directors of the Bio-Process Systems Alliance (BPSA). He has been participating since 2012 in several single-use technology industry work groups, from BPSA, BioPhorum Operations Group (BPOG), American Society of Mechanical Engineers (ASME BPE) and ASTM International.

Stefan R. Schmidt, COO/Head of Operations, BioAtrium AG

Dr. Stefan R. Schmidt currently serves as COO/Head of Operations at BioAtrium AG, a Lonza and Sanofi JV in Switzerland. Previously he held the position as CSO and other senior executive roles at Rentschler Biopharma with overall responsibilities for development, production and innovation. Before that, he was CSO at ERA Biotech in Barcelona, directing the company's R&D efforts. Prior to that, he worked at AstraZeneca in Sweden where he led the unit of Protein Sciences as Associate Director. He started his leadership career in Munich more than 20 years ago where he built up protein biochemistry teams for Connex and GPC-Biotech. During his academic education he earned a PhD in Biochemistry and an MBA in Marketing.

Paul Spencer, Owner, PharmaMercenary

Paul Spencer has a BS in Chemical Engineering, an MBA, and is a licensed PE in two states. Mr. Spencer started his career in the fermentation and purification of Monoclonal Antibody based diagnostic products. This included work conjugating MAbs to diagnostic markers. Later work has involved research to commercial manufacturing of innovative therapies, as well as high volume/high complete products. Mr. Spencer has 35 years of technical experience in a many of the therapeutic facilities. He provides a highly technical capability to those pharmaceutical units due to his 35 years of experience. He is a person that has been involved in significant improvements to the marketplace, often considered a thought leader in multiple unit operations and technological developments.

Christoph Winterhalter, Senior Vice President, Business Development, AGC Biologics

Dr. Christoph Winterhalter has 24 years of experience in Life Science and serves currently as Senior Vice President Business Development at AGC Biologics, a global biopharmaceutical CDMO with sites in US, EU and Japan. Before that he was heading

Business Development globally at Rentschler Biopharma with a strong contribution to the tremendous growth phase from 2013-2017 where sales more than tripled. Prior to joining Rentschler Biopharma, Christoph Winterhalter served as Vice President Biosolutions at Wacker Chemical Corporation in Michigan US heading a 100 MIL USD business for Life Science. Before that he held several positions at Wacker Chemie AG in Germany, where he started in 1995 to develop the first fermentation route to cysteine by metabolic design in *E. coli*. Christoph Winterhalter holds a Ph.D. in Microbiology at the Technical University of Munich.

16th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production • April 2019

*A Study of Biotherapeutic Developers and Contract
Manufacturing Organizations*

CONTENTS

METHODOLOGY	XXVI
--------------------------	-------------

CHAPTER 0: DEMOGRAPHICS	1
Introduction	1
0-1 Respondents' Area of Involvement.....	1
0-2 Respondents Qualifications	4
0-3 Facility Locations	6
0-4 Areas of Biopharmaceutical Manufacturing Operations	8
0-5 Production Operations, Phase of Development.....	10
0-6 Employees at Facility	13
0-7 Batches Run at Facility per Year	14
0-8 Single-Use Bioreactor Capacity In Use at Site	16
0-9 Stainless Steel Bioreactor Capacity In Use at Site	17

CHAPTER 1: INTRODUCTION AND DISCUSSION.....	19
1-1 Introduction: The Pharmaceutical and Biopharmaceutical Industries	19
1-2 Current Status and Market Trends.....	24
1-3 Market Potential.....	28
1-4 Biopharmaceuticals and Biosimilars in the Pipeline	30
FDA Biopharmaceutical Approvals.....	34
1-5 Global Biopharmaceutical and Recombinant Protein/MAB Markets	37
Overall Health of the Biopharmaceutical Sector	38
U.S. Industry Leadership Continues	40
Biopharmaceuticals in the Rest of the World	41
1-6 Biopharmaceutical Markets by Product Class	45
Monoclonal antibodies (mAbs) are the Leading Product Classes	45

1-7	Animal Derived Products and Biopharmaceuticals	47
1-8	Future Trends in the Biopharmaceutical Industry	48
CHAPTER 2: FUTURE OF BIOPROCESSING: EXPERTS' PERSPECTIVE		53
2-1	Worldwide Biopharmaceutical CMO Capacity Analysis	53
2-2	Rapid Identification of Microbial Contamination.....	53
2-3	Suppliers' Contributions to Bioprocessing Advances	53
2-4	Make vs. Buy (In- vs. Outsourcing): Causes, criteria, and consequences	53
2-5	Mergers & Acquisitions	53
2-6	China's Advances in Biopharmaceutical Contract Manufacturing.....	53
CHAPTER 3: EMERGING ISSUES IN BIOPHARMACEUTICAL MANUFACTURING		89
3-1	Industry Trends in 2019	89
	Introduction	89
	Productivity and Cost Reductions	90
	Novel Bioprocessing Systems/Innovations	92
	Novel Bioprocessing Systems/Innovations – Biomanufacturers vs. CMOs	94
3-2	Budget Issues in 2019.....	96
	Budget Change Comparisons	99
3-3	Operational Changes	102
3-4	New Bioprocessing Products Development Opportunities in 2019.....	103
	Upstream New Product Areas of Need	104
	Downstream New Product Areas of Need	108
	Previous Year Areas Include:.....	110
	Other General New Product Areas of Need.....	112
	Innovations in Single-use/Disposable Equipment.....	115
	Discussion of Needed Single-use Innovations.....	115
	Other Areas for Innovation	118
	New Product Development Areas: Biotherapeutic Developers vs. CMOs	118
	New Product Development Areas: U.S. vs. Western Europe and ROW.....	120
3-5	Factors in Biomanufacturing Creating Improvements	122
	Factors Improving Biomanufacturing Performance, 2010 - 2015	122
	Factors Improving Biomanufacturing Performance, Biotherapeutic Developers vs. CMOs (2015 Data)	122
	Factors Improving Biomanufacturing Performance, U.S. vs. Western Europe vs. ROW (2015 Data).....	123
3-6	Discussion	124
3-7	Cost-Cutting Actions & Development Timelines	124
	Cost-Cutting Changes Specific to Outsourcing	126
3-8	Average Cost per Gram Recombinant Protein	128
3-9	Assay Development	129
	Biomanufacturing Assay Areas Required: Biomanufacturers vs. CMOs	131

3-10 Cell and Gene Therapy Platforms.....	133
Cell and Gene Therapy Manufacturing Advancements (2018 data)	135
Cell and Gene Therapy Manufacturing Improvements, Systems, Platforms and Infrastructure.....	136
3-11 Selecting Bioreactors in New Facilities	138
3-12 Discussion: Industry Trends and Issues	142
Industry Growth and Adaptation.....	142
Cost Cutting Trends	142
Trends in Assay Development	143
Trends in Speeding Development and Approval Timelines.....	143
Trends in Bioprocessing Industry Desire for Improved Products and Services	144
 CHAPTER 4: CAPACITY UTILIZATION.....	 145
4-1 Capacity Utilization Trends	145
Capacity Utilization Definitions.....	145
Relevance of Capacity Utilization	145
Capacity Utilization in Biomanufacturing, 2019.....	147
Capacity Utilization Changes Since 2004	148
Average Growth Rate in Capacity Utilization, 2006-2019	150
4-2 Capacity Utilization: CMOs vs. Biotherapeutic Developers	150
4-3 Capacity Utilization: U.S. vs. Western European Manufacturers.....	152
4-4 Respondents' Current Total Production Capacity.....	154
Mammalian Cell Culture.....	154
Estimated Bioreactor Capacity Distribution, Biotherapeutic Developers and CMOs	158
Biopharmaceutical Developers/Manufacturers as CMOs	160
Microbial Fermentation Capacity	161
Cell or Gene Therapy Capacity.....	162
4-5 Discussion: Capacity Trends	164
4-6 Range of Titers with mAb Production	165
Annual mAb Titer Changes, 2008-2019.....	167
4-7 Discussion: Capacity and Industry Trends.....	168
Capacity Utilization	168
 CHAPTER 5: CURRENT AND FUTURE CAPACITY CONSTRAINTS	 175
5-1 Current Capacity Constraints	175
Respondents Experiencing No Capacity Constraints	177
Respondents' Perception of Capacity Constraints, 2004-2019.....	177
Perception of Capacity Constraints: Biotherapeutic Developers vs. CMOs	179
Capacity Constraints: U.S. vs. Western European Biotherapeutic Developers & CMOs	182
5-2 Expected Capacity Constraints	184
Respondents' Expectations of Capacity Constraints by 2024.....	184

Expected Capacity Constraints by 2024: Comparing 2004 to 2019 Data.....	186
Expected Capacity Constraints by 2024: Biotherapeutic Developers vs. CMOs	189
Expected Capacity Constraints by 2024: U.S. vs. Western Europe.....	191
5-3 Factors Impacting Future Production Capacity	193
Factors Creating Future Capacity Constraints.....	193
Factors Creating Future Capacity Constraints, 2008 - 2019.....	195
Factors Creating Future Capacity Constraints: Biotherapeutic Developers vs. CMOs	197
CMO Capacity Bottleneck Projections, in Retrospect.....	199
Biotherapeutic Developers' Capacity Bottleneck Projections, in Retrospect	199
Factors Creating Capacity Constraints: U.S. vs. Western European Respondents	200
5-4 Key Areas to Address to Avoid Future Capacity Constraints	202
Analysis of Areas to Avoid Capacity Constraints: Changing Perspectives, 2006-2019	204
Key areas to Address to Avoid Capacity Constraints; Biotherapeutic Developers vs. CMOs	207
Key Areas to Address to Avoid Capacity Constraints: U.S. vs. Western Europe	209
5-5 Discussion	211
Overall Capacity Constraints	212
CHAPTER 6: FUTURE CAPACITY EXPANSIONS	217
6-1 Planned Future Capacity Expansions	217
Planned Future Capacity Expansions, 2009-2024.....	218
Planned Future Capacity Expansions by 2024: CMOs vs. Biotherapeutic Developers.....	220
Planned Five-Year Capacity Expansion: U.S. vs. Western European Manufacturers	221
Planned Future Capacity Expansions of >100%.....	222
CHAPTER 7: OUTSOURCING TRENDS IN BIOPHARMACEUTICAL MANUFACTURING.....	225
Why Outsource?	225
Relating Outsourcing to Workforce Reduction	226
Strategic Manufacturing Planning	226
Future Projections.....	227
7-1 Current Outsourcing by Production System	228
Facilities Currently Outsourcing No Production (All Production "In-house"), 2006-2019	232
7-2 Future Outsourcing.....	234
Biotherapeutic Developers' Outsourcing, 5-Year/2024 Projections, by System.....	234
Biotherapeutic Developers Outsourcing Some Production in 2024	236
7-3 Outsourced Activities in Biopharmaceutical Manufacturing	238
Comparison of Biomanufacturers' Outsourcing, (2010-2019).....	240
Increased Outsourced Activities, 24-month Projections	242

Outsourcing Activities Projected at “Significantly Higher Levels”, Comparison of 2010-2019 Trends	244
Average Percentage of Activities Outsourced Today	247
Comparison of Outsourcing Activities, 2010-2019	249
Change in Spending on Outsourcing Activities	252
7-4 Critical Outsourcing Issues.....	254
Selecting a CMO: (2018 data)	254
Selecting a CMO, 2006-2018.....	256
Changes in Critical Issues when Considering a CMO, 2006-2018	258
7-5 CMOs’ Problems with Their Clients.....	260
7-6 Country Selections for International Outsourcing (Off-shoring) of Biomanufacturing.....	263
U.S. vs. Western European Respondents’ Outsourcing Destinations	266
Western European Respondents’ Outsourcing Destinations	271
5-Year Projection for Biomanufacturing International Outsourcing/Off-shoring	274
7-7 Offshoring Trends	276
5-Year Projection for Percentages of Biomanufacturing International Outsourcing/Off-shoring	278
7-8 Discussion of Outsourcing and Offshoring.....	281
Selecting a CMO.....	285

CHAPTER 8: DISPOSABLES AND SINGLE-USE SYSTEMS IN BIOPHARMACEUTICAL MANUFACTURING..... 289

8-1 Use of Disposables and Single-Use Systems	289
Disposables Applications in Biopharmaceutical Manufacturing	290
Trends in Disposable Applications: 2006-2019	292
Average Annual Growth Rate for Disposables: Market Penetration/Usage	295
13-Year Average Growth in Disposable Applications, Percentage-Point Gains.....	296
Disposable Use by Stage of Production/Application	298
Use of Disposables: CMOs vs. Biotherapeutic Developers	300
8-2 Leachables and Extractables	302
Paying for L&E Testing, 2018, vs. 2016-2009	302
8-3 Reasons for Increasing Use of Disposables & Single-Use Systems	304
Single Most Critical Reason for Increasing the Use of Disposables (2018 data).....	304
8-4 Factors That May Restrict Use of Disposables	306
Most Critical Reasons for Restricting Use of Disposables	306
Most Important Reasons for Not Increasing Use of Disposables, 2008-2019	308
Most Important Reasons for Restricting Use of Disposables: Biotherapeutic Developers vs. CMOs	311
Top Reasons for Not Increasing the Use of Disposables: U.S. vs. Western Europe	313
8-5 Suppliers’ Expectations for Standards Setting Bodies	315
8-6 Need for Single-use Sensors, and Bioreactor Attributes	316

Single-Use Adoption Issues (2018 data).....	316
Single-use Adoption Factors, U.S. vs. Western Europe (2018 data)	317
Single-Use Sensor Technologies (2012-2017, 2019) Data.....	318
8-7 Satisfaction with Single-Use Device Vendors	320
Single-Use Attribute Importance Analysis	322
Single-Use Suppliers' Delivery Problems, 2013-2019	324
8-8 Single Use Operations and Trends.....	326
Percentage of Unit Operations that Are Single-Use.....	326
Distribution of Responses	328
8-9 Discussion of Single-use Bioprocessing	329
Single-use Advantages	329
Growth in the Use of Single-use Systems	330
Downstream Single-use Systems Usage.....	331
CMOs' Use of Single-use Equipment.....	331
Downstream Bottlenecks Persist	332
Modular: The Next Trend after Single-Use?.....	333
Single-use Equipment Sourcing, Quality Issues, and L&E Testing	333
 CHAPTER 9: DOWNSTREAM PURIFICATION	 341
9-1 Impact of Downstream Processing on Capacity	341
Impact of Downstream Processing on Capacity, Biopharmaceutical Developers vs. CMOs	344
Impact of Downstream Processing on Capacity, U.S. vs. Western European Biomanufacturers	345
9-2 Specific Purification Step Constraints	347
Changes in Impact on Capacity of Purification Steps, 2008-2019	348
Specific Purification Step Constraints, U.S. vs. Western European Biomanufacturers	350
9-3 Downstream Purification Issues	351
Protein A and Alternatives (2017 data).....	351
Changes in Perception of Protein A and Alternatives.....	352
Protein A Downstream Purification Issues, U.S. vs. Western Europe (2017 data) ..	354
9-4 mAb Purification Capacity Estimates	355
Upstream Production Titer vs. Max Capacity.....	355
9-5 New Downstream Processing Technologies	357
New Downstream Processing Solutions; 2010 – 2019	359
New Downstream Processing Technologies; Biotherapeutic Developers vs. CMOs	362
New Downstream Processing Technologies: U.S. vs. Western Europe	364
9-6 Improvements to Downstream Operations	366
Comparison of New Downstream Technology Implementation; Biomanufacturers vs. CMOs	368
Comparison of New Downstream Technology Investigations; U.S. vs. W. Europe vs. ROW	370

9-7 Discussion	372
Upstream Expression Titer Trends and Impact on Downstream Operations	372
Downstream Processing Solutions	372
 CHAPTER 10: QUALITY ISSUES, BATCH FAILURES, AND PAT IN BIOPHARMACEUTICAL MANUFACTURING.....	377
10-1 Quality Initiative Implementation	378
Comparison of Quality Initiative Implementation, 2009 - 2018	380
Quality Initiatives Are Becoming Commonplace and the New Industry Norm	382
Challenges to Implementing PAT, QbD and other Quality Initiatives.....	382
10-2 Hurdles to Implementing Process Analytical Technology	383
Trends in PAT, 2008-2019	383
PAT Adoption Will Increase	385
10-3 Batch Failure Frequency in Biopharmaceutical Manufacturing	387
10-4 Primary Cause of Batch Failures, Percentages of Failures	389
Quality Problems Traced to Vendors	395
Process Information Needs and Value Drive Automation	396
10-5 Quality Problems in BioManufacturing Attributed to Vendors	397
10-6 Discussion	399
Supply Management Issues with Single-Use Systems.....	399
 CHAPTER 11: HIRING, EMPLOYMENT GROWTH, AND TRAINING IN BIOPHARMACEUTICAL MANUFACTURING.....	401
Introduction	401
No Substitute for on-the-job Training	402
11-1 Hiring Trends	402
Trends in New Hires, by Area; 2008 – 2019	403
11-2 Hiring in 2024: 5-year Trends	405
11-3 Hiring Challenges Today.....	406
Hiring Difficulties; 2010 - 2019	408
11-4 Training in Biopharmaceutical Manufacturing	412
Changes in Training for New Manufacturing Employees, 2009-2018	413
11-5 Discussion	414
Options Developing for Bioprocessing Training	414
Continued Growth in Biopharmaceutical Manufacturing Jobs	415
 CHAPTER 12: CONTINUOUS BIOPROCESSING	417
Introduction	417
Adoption of Continuous Bioprocessing	418
Implementation of Continuous Bioprocessing.....	419
Continuous Processing – Present and Future Challenges	420
Continuous Bioprocess and Process Intensification	424

12-1 Perfusion Operations and Continuous Bioprocessing Operations Issues	426
Perfusion vs. Batch Fed Bioprocessing (2018 data)	429
12-2 Perfusion Operations and Continuous Bioprocessing Trends	431
12-3 Discussion	433
Continuous Bioprocessing: Trends and Opportunities	433
Perfusion: Progress in Adoption.....	434

CHAPTER 13: SUPPLIERS TO BIOPHARMACEUTICAL MANUFACTURING AND LIFE SCIENCES..... 437

Introduction	437
13-1 Demographics	437
Areas of Involvement	437
Location of Vendor Sales	440
Respondents' Primary Job	442
13-2 Growth Rate of Sales by Suppliers	443
Average Industry Growth Rate, By Segment	444
Vendor Sales Growth Rates, by Industry Segment, 2007 - 2019	445
Supplier Annual Sales, Distribution	447
13-3 Discussion of Vendor and Industry Growth	449
13-4 Budget Issues and Problems Faced by Industry Suppliers.....	450
Budget Challenges in 2018.....	450
Vendor Average Budget Changes for 2009 -2018	452
Vendor Pricing Changes	454
Past Year and Expected Price Changes (2009-2019)	455
Supplier Budget Issues	457
13-5 Cost Cutting Actions by Vendors.....	457
Cost Cutting Actions, By Segment	459
13-6 Problems Clients Have with Their Vendors	461
13-7 Vendor Expansion Plans.....	463
Biopharma Vendor Business Trends, 2010 - 2019	465
13-8 New Technology Areas in Development	
by Vendors	467
Suppliers' Development of Innovative Technologies	471
Suppliers' R&D Spending/Budgets for New Products/Services	472
13-9 Sales Staff Training	473
Days of Training Provided by Suppliers	473
Areas where Training May Help Sales Staff Perform, Trends	
2010 - 2019.....	474
Clients' Demands on Vendors.....	476

13-10 Biopharma Vendors' Financial Outlook for 2019	478
13-11 CMO Pricing Changes for Biopharmaceutical Services.....	480
13-12 Discussion of Biopharma Suppliers.....	482
Bioprocessing Vendors Will See Continued Market Growth	482
Single-use Systems Continue to Drive Sales.....	482
Trends Favor Increased Vendor Sales.....	483
Vendors are Offering More Services, Going for Larger Sales	483
Biopharma Suppliers in Emerging Regions	484

FIGURES

Fig 0.1:	Area of Primary Involvement in Biopharmaceutical Manufacturing, 2010 to 2019	3
Fig 0.2:	Respondents' Job Responsibilities, 2011 – 2019	5
Fig 0.3:	Facility Location	6
Fig 0.4:	Facility Location, by Region	7
Fig 0.5:	Biopharmaceutical Manufacturing Systems, (2007-2019) Trends.....	9
Fig 0.6:	Phase of Development of Surveyed Respondents, 2006-2019	11
Fig 0.7:	Phase of Development of Surveyed Respondents (U.S. vs. Western Europe)	12
Fig 0.8:	Distribution of Employees at Facility, and Organization.....	13
Fig 0.9:	Distribution of Total Batches Run at Facility Last Year, by Scale of Production	15
Fig 0.10:	Distribution of Largest SINGLE-USE Bioreactor Capacity	16
Fig 0.11:	Distribution of Largest STAINLESS Bioreactor Capacity	18
Fig 1.1:	U.S. Biosimilars Launchable Dates 2012-2014 by Current Cumulative Reference Product Sales (\$Millions)	33
Fig 1.2:	U.S. Biosimilars Launchable Dates 2012-2014 by Current Cumulative Reference Product Sales (\$Millions)	33
Fig 1.3:	Number of FDA Approvals of New Biopharmaceutical Products 1982-2018	34
Fig 2.1:	Total CMO Facilities and Capacity by Bioprocessing Capacity Scales	55
Fig 2.2:	Distribution of All and CMO Facilities by Facility Capacity Ranges.....	55
Fig 2.3:	The 10-C criteria for make-or-buy decisions.....	73
Fig 2.4:	A scenario-based approach	78
Fig 2.5:	A make-or-buy decision tree	79
Fig 2.6:	Integration of services in the CDMO value chain.....	80
Fig 3.1:	SINGLE most important biomanufacturing trend or operational area, 2014-2019	91
Fig 3.2:	Novel Bioprocessing Systems/Innovations to Evaluate in Next 12 Months	93
Fig 3.3:	Novel Bioprocessing Systems/Innovations to Evaluate in Next 12 Months (Biomanufacturers vs. CMOs).....	95
Fig 3.4:	Biomanufacturers' Budget Shifts in 2019	97
Fig 3.5:	Approximate Average Change in Biomanufacturers' Budgets for 2019.....	98
Fig 3.6:	Average Biomanufacturers' Budget Change, 2009-2019	101
Fig 3.7:	New Product Development-Upstream Focus Areas	105
Fig 3.8:	Upstream New Product Development Areas Cited Where Suppliers Should Focus Development Efforts (2010-2019)	107
Fig 3.9:	Downstream New Product Development Areas Cited Where Suppliers Should Focus Development Efforts, 2019.....	109
Fig 3.10:	New Product Development-Downstream Focus Areas (2010-2019)	111
Fig 3.11:	New Product Development – General Focus Areas, Biomanufacturers & CMOs, 2019.....	113
Fig 3.12:	New Product Development – General Focus Areas, 2010-2019	114
Fig 3.13:	Top 10 New Product Development Areas of Interest: Biomanufacturers vs. CMOs.....	119

Fig 3.14:	Top 10 New Product Development Areas of Interest: U.S. vs. Western Europe and ROW.....	121
Fig 3.15:	Cost-Cutting Changes: Actions Undertaken During “Past 12 Months” Comparing 2011-2016, 2019.....	125
Fig 3.16:	Cost-Cutting Changes, Outsourced Jobs, by Segment, and Geography (2011-2016, 2019).....	127
Fig 3.17:	Distribution, Average Cost per Gram for PRIMARY Recombinant Protein, 2019.....	128
Fig 3.18:	Biomanufacturing Assay “Areas” Urgently Requiring New, Improved Testing Methods, 2011 -2015, 2018-2019.....	130
Fig 3.19:	Biomanufacturing Assay “Areas” Urgently Requiring New, Improved Testing Methods; Biomanufacturers vs. CMOs (2019 data).....	132
Fig 3.20:	Future Cell and Gene Therapy Platforms, 2019.....	134
Fig 3.21:	Cell and Gene Therapy Manufacturing Advancements in 5 Years (2023) to Avoid Bottlenecks	135
Fig 3.22:	Most Needed Cell & Gene Therapy Manufacturing Improvements, Systems, Platforms and Infrastructure.....	137
Fig 3.23:	Likelihood of Implementing Bioreactor, by Type, 2017.....	140
Fig 3.24:	Likelihood of Implementing Single-use Bioreactors, Clinical Scale, 2012-2017	141
Fig 4.1:	Capacity Utilization, By System.....	148
Fig 4.2:	Capacity Utilization, By System, 2004-2019	149
Fig 4.3:	Change in Capacity Utilization, CAGR, 2006-2019.....	150
Fig 4.4:	Capacity Utilization, By System, Biotherapeutic Developer vs. CMOs, 2019.....	152
Fig 4.5:	Capacity Utilization, By System, U.S. vs. Western Europe, 2019	154
Fig 4.6:	Current Production Capacity Distribution, Mammalian Cell Culture	156
Fig 4.7:	Production Capacity Distribution, Mammalian Cell Culture, 2011-2019.....	157
Fig 4.8:	Bioprocessing Concentration, Capacity Data, 2019.....	158
Fig 4.9:	Current Production Capacity Distribution, Microbial Fermentation.....	162
Fig 4.10:	Current Production Capacity Distribution, Cell or Gene Therapy	163
Fig 4.11:	Range of Titers for mAbs Obtained at Various Production Scales, 2019 Distribution	166
Fig 4.12:	Average mAb Titer Trend 2008-2019.....	167
Fig 5.1:	Capacity Constraints, by Stage of Production	176
Fig 5.2:	Capacity Constraints, 2004 -2019.....	178
Fig 5.3:	Capacity Constraints Trends, 2004-2019	179
Fig 5.4:	Capacity Constraints, Biotherapeutic Developers vs. CMOs	181
Fig 5.5:	Capacity Constraints, U.S. vs. Western Europe.....	183
Fig 5.6:	Expectations of Capacity Constraints by Stage of Production: Five-year Projections	185
Fig 5.7:	Expectations of Capacity Constraints: Five-year Projections Made in 2004-2019 ..	187
Fig 5.8:	Expectations of Capacity Constraints: Five-year Projections Made in 2004 thru 2024 (Trend Line)	188
Fig 5.9:	Five-year Projections for Capacity Constraints: Biotherapeutic Developers vs. CMOs.....	190

Fig 5.10:	Five-year Projections for Capacity Constraints: U.S. vs. Western Europe	192
Fig 5.11:	Factors Creating Future Capacity Constraints in Five Years	194
Fig 5.12A:	Factors Creating Future Capacity Constraints, 2008-2019.....	195
Fig 5.12B:	Factors Creating Future Capacity Constraints, 2008-2018.....	196
Fig 5.13:	Factors Creating Future Capacity Constraints: Biotherapeutic Developers vs. CMOs	198
Fig 5.14:	Factors Creating Future Capacity Constraints, U.S. vs. Western European Biomanufacturers.....	201
Fig 5.15:	Key Areas to Address to Avoid Capacity Constraints.....	203
Fig 5.16A:	Key Areas to Address to Avoid Capacity Constraints; 2006-2019	205
Fig 5.16B:	Key areas to Address to Avoid Capacity Constraints; 2006-2019.....	206
Fig 5.17:	Key Areas to Address to Avoid Capacity Constraints; Biotherapeutic Developers vs. CMOs	208
Fig 5.18:	Key Areas to Address to Avoid Capacity Constraints; U.S. vs. Western Europe	210
Fig 6.1:	Industry Average Planned Production Increase by 2024	218
Fig 6.2:	Planned Future Capacity Expansion: Five-Year Estimates, 2009–2024	219
Fig 6.3:	Planned Future Capacity Expansion: Five-year Estimates: Biotherapeutic Developers vs. CMOs	220
Fig 6.4:	Planned Future Capacity Expansion: Five-Year Estimates: U.S. vs. Western Europe.....	222
Fig 6.5:	Percentage of Respondents Projecting Production Increases over 100% by 2024: Five-year Trend	223
Fig 7.1:	Current Percent Production Outsourced; by System	231
Fig 7.2:	Biopharmaceutical Manufacturing Facilities Outsourcing NO Production, 2006-2019	233
Fig 7.3:	Future Outsourcing: Percent Production Outsourced; by 2024, by System.....	235
Fig 7.4:	Five-year Projections: % Biotherapeutic Developers Planning to Outsource at Least Some Production; Projections made 2007-2019.....	237
Fig 7.5:	Percent of Biomanufacturers Outsourcing <i>at Least Some</i> Activity Today	239
Fig 7.6A:	Percent of Biomanufacturers Outsourcing at Least Some Activity Today, 2010 – 2019	241
Fig 7.6B:	Percent of Biomanufacturers Outsourcing at Least Some Activity Today, 2010 – 2019	242
Fig 7.7:	Outsourcing Activities Projected to be Done at “Significantly Higher Levels” in 2 Years	243
Fig 7.8A:	Outsourcing Activities Projected to be Done at “Significantly Higher Levels” in 2 Years, 2010 - 2019 Trends.....	245
Fig 7.8B:	Outsourcing Activities Projected to be Done at “Significantly Higher Levels” in 2 Years, 2010 - 2019 Trends.....	246
Fig 7.9:	Current Outsourcing: Average Percentage of Activity Outsourced Today	248
Fig 7.10A:	Estimated Average Percent of Activity Outsourced by Facilities, 2010 thru 2019...	250
Fig 7.10B:	Estimated Average Percent of Activity Outsourced by Facilities, 2010 thru 2019...	251
Fig 7.11:	Change in Spending on Outsourcing for R&D or Manufacturing, 2012 - 2019	253

Fig 7.12:	Outsourcing Issues: BioManufacturing by Contract Manufacturing Organizations	255
Fig 7.13:	Important Outsourcing Issues: BioManufacturing by Contract Manufacturing Organizations, Trends 2006-2018	257
Fig 7.14:	Important Outsourcing Issues: Response Shifts Over Time 2006-2018, Percentage Point Differences	259
Fig 7.15:	Most Common Mistakes Biopharmaceutical Sponsors Make with their CMOs, 2018	261
Fig 7.16:	Most Common Mistakes Biopharmaceutical Sponsors Make with their CMOs, 2010-2013; 2018	262
Fig 7.17:	Country Selections as Destination for International Outsourcing of BioManufacturing (All Respondents), in the next five years, 2024	265
Fig 7.18A:	Percent U.S. Respondents Considering Country as "Possible" Outsourcing Destination, next five years, 2024	267
Fig 7.18B:	Percent U.S. Respondents Considering Country as "Possible" Outsourcing Destination, next five years, 2024	268
Fig 7.19:	Percent U.S. Respondents Considering Country as "Strong Likelihood" or "Likelihood" as Outsourced Capacity Destination, next five years, 2024.....	269
Fig 7.20:	Percent Western European Respondents Considering Country as "Possible" Outsourcing Destination, next five years, 2024	272
Fig 7.21:	Percent European Respondents Considering Country as "Strong Likelihood" or "Likelihood" as Outsourced Capacity Destination.....	273
Fig 7.22:	Percent of Biomanufacturing Operations Off-shored (International Outsourcing) within 5 Years (2024)	275
Fig 7.23:	Percent Biomanufacturers Performing at Least "Some" International Outsourcing/Off-shoring during Next 5 Years (2011-2019).....	277
Fig 7.24:	Estimated % Operations Done as International Outsourcing/Off-shoring during Next 5 Years (2011-2019).....	279
Fig 8.1:	Usage of Disposables in Biopharmaceutical Manufacturing, Any Stage of R&D or Manufacture.....	291
Fig 8.2A:	Usage of Disposables in Biopharmaceutical Manufacturing, Any Stage of R&D or Manufacture: 2006-2019.....	293
Fig 8.2B:	Usage of Disposables in Biopharmaceutical Manufacturing, Any Stage of R&D or Manufacture: 2006-2019.....	294
Fig 8.3:	Average Annual Growth Rate, Disposables, 2006-2019.....	296
Fig 8.4:	13-Year Percentage-Point Change in First Usage of Disposables, 2006-2019	297
Fig 8.5:	Usage of Disposables in Biomanufacturing by Stage of Manufacture (R&D–Commercial)	299
Fig 8.6:	Usage of Disposables in Biopharmaceutical Manufacturing: Biotherapeutic Developers vs. CMOs.....	301
Fig 8.7:	Willingness to Pay for Useable Leachables and Extractables Data (2018 Data)	303
Fig 8.8:	Single Most Critical Reason for Increasing Use of Disposables, 2009 - 2018.....	305
Fig 8.9:	Top Reasons for Not Increasing Use of Disposables, 2019	307

Fig 8.10A: Top Reasons for Not Increasing Use of Disposables, 2008-2019.....	309
Fig 8.10B: Top Reasons for Not Increasing Use of Disposables, 2008-2019.....	310
Fig 8.11: Top Reasons for Not Increasing Use of Disposables, Biotherapeutic Developers vs. CMOs	312
Fig 8.12: Top Reasons for Not Increasing Use of Disposables, U.S. vs. Western Europe.....	314
Fig 8.13: Suppliers' Perception of Organizations Responsible for Establishing Standards for Single-use Devices (2017 data)	315
Fig 8.14: Single-use / Disposable Device Adoption Factors (2018 data).....	316
Fig 8.15: Single-use / Disposable Device Adoption Factors; U.S. vs. Western Europe, 2018 data.....	317
Fig 8.16: Need for Improved Single-Use Sensors, 2012-2017, 2019	319
Fig 8.17: Single-Use Product Vendor Satisfaction Factors, 2008-2019.....	321
Fig 8.18: Importance of Single-Use Product Attributes vs. Level of Vendor Satisfaction	323
Fig 8.19: Percentage Point Gap between Importance of SUS Product Attributes and Level of Satisfaction, 2013-2019.....	325
Fig 8.20: Estimated Percentage of Facilities' Unit Operations that Are "Single-Use" (2014 - 2019).....	327
Fig 8.21: Distribution of Responses, % Single-Use Devices in Biomanufacturing	328
Fig 9.1: Impact of Downstream Processing on Overall Capacity, 2008-2019	343
Fig 9.2: Impact of Downstream Processing on Overall Capacity; Biotherapeutic Developers vs. CMOs.....	344
Fig 9.3: Impact of Downstream Processing on Overall Capacity; U.S. vs. Western Europe.....	346
Fig 9.4: Impact on Capacity of Depth, Chromatography and UF Purification Steps	348
Fig 9.5: Impact on Capacity of Purification Steps: Experiencing at "Significant" or "Severe" Constraints, 2008 – 2019	349
Fig 9.6: Impact on Capacity of Purification Steps, U.S. vs. Western Europe.....	350
Fig 9.7: Issues Regarding Protein A Usage (2017 data)	351
Fig 9.8: Issues Regarding Protein A Usage, 2009 - 2017.....	353
Fig 9.9: Issues Regarding Protein A Usage; U.S. vs. Western Europe.....	354
Fig 9.10: mAb Operations: Upstream Production Titer (Distribution of Responses, 2014 -2016, 2018-2019 Data).....	355
Fig 9.11: Bioreactor Yield at which DOWNSTREAM Purification Train Becomes Bottlenecked.....	356
Fig 9.12: New Downstream Processing Solutions, 2019.....	358
Fig 9.13A: New Downstream Processing Solutions Comparison 2010-2019.....	360
Fig 9.13B: New Downstream Processing Solutions Comparison 2010-2019.....	361
Fig 9.14: New Downstream Processing Solutions; Biotherapeutic Dev. vs. CMOs.....	363
Fig 9.15: New Downstream Processing Solutions; U.S. vs. Western Europe	365
Fig 9.16: Improving Downstream Operations, 2011 - 2019	367
Fig 9.17: Improving Downstream Operations; Biomanufacturers vs. CMOs	369
Fig 9.18: Improving Downstream Operations (U.S. vs. Western Europe vs. ROW).....	371

Fig 10.1:	Quality Initiative Implemented Currently, or within Next 12 Months (2018 DATA)	379
Fig 10.2:	Quality Initiative to be Implemented in “Next 12 Months,” Comparing 2009 - 2018	381
Fig 10.3:	Hurdles Hindering Implementation of PAT (2008 – 2019).....	384
Fig 10.4:	Batch Failure Frequency Distribution, 2009 – 2019	388
Fig 10.5:	Average Rates of Failure, by Primary Cause, and Phase of Manufacture	391
Fig 10.6:	Average Rates of Failure, by Primary Cause, and Phase of Manufacturing 2009 - 2019 (Commercial Manufacture)	393
Fig 10.7:	Average Rates of Failure, by Primary Cause, and Phase of Manufacturing 2009 - 2019 (“Clinical” Scale).....	394
Fig 10.8:	Quality Problems Traced to Vendors; 2008 – 2018.....	398
Fig 11.1:	New Hires in Biopharmaceutical Manufacturing (2019)	403
Fig 11.2:	Estimated Hiring, by Area, 2008-2019	404
Fig 11.3:	New Hires in Biopharmaceutical Manufacturing (2024)	405
Fig 11.4:	Areas Where Hiring Difficulties Exist in Biopharmaceutical Operations	407
Fig 11.5:	Areas Where Hiring Difficulties Exist in Biopharmaceutical Operations; 2010 – 2019	409
Fig 11.6:	Areas Where Hiring Difficulties Exist in Biopharmaceutical Operations, U.S. vs. Western Europe	411
Fig 11.7:	Training for New Operations/Manufacturing Employees (2018 data).....	413
Fig 11.8:	Average Annual Changes in Training for New Operations/Manufacturing Employees, 2009 – 2018.....	413
Fig 12.1:	Changing the way culture is viewed	420
Fig 12.2:	Example of an operational workflow diagram for an upstream process.....	421
Fig 12.3:	Triangle of Pharmaceutical Facility Design	422
Fig 12.4:	The QbD principles as laid out by ICH Q8 and Q11.....	423
Fig 12.5:	Future of Continuous Bioprocessing and Process Intensification.....	425
Fig 12.6:	Perfusion Operations Issues: Comparison 2010 - 2016 (2016 data)	428
Fig 12.7:	Concerns Over Perfusion Processes vs. Batch-fed Processes in Bioprocessing ...	430
Fig 12.8:	Facilities Evaluating CBP Technologies Over Next 12 months (Upstream vs. Downstream), 2016-2019	432
Fig 13.1:	Area of Biopharmaceutical Involvement, Vendor.....	438
Fig 13.2:	Area of Biopharmaceutical Involvement, Vendor Comparison 2010 to 2019	439
Fig 13.3:	In Which Geographic Regions/Countries Does Your Company Currently Actively Sell, 2008 - 2019.....	441
Fig 13.4:	Respondents’ Primary Job Function	442
Fig 13.5:	Average Annual Vendor Sales Growth Rate, 2007 - 2019	443
Fig 13.6:	Biopharmaceutical Supply Market Segment Sales Growth Distribution	444
Fig 13.7:	Average Annual Vendor Segment Sales Growth Rates, 2019	445
Fig 13.8:	Average Annual Vendor Sales Growth Rate, 2007 - 2019, by Segment.....	446
Fig 13.9:	Vendors’ Approx. Annual Sales to Biopharmaceutical Segment %, 2012-2019.....	448

Fig 13.10: Vendors' Average Budget Change, 2019	451
Fig 13.11: Vendors' Average Budget Change for 2009 - 2019, Summary.....	453
Fig 13.12: Vendors' Average Pricing Changes	454
Fig 13.13: Vendors' Average Pricing Changes, 2009-2018 Actual and 2019 projected	456
Fig 13.14: Actions undertaken to reduce overall costs, prior 12 months, 2011-2017	458
Fig 13.15: Actions undertaken to reduce overall costs in past 12 months, By Segment (2017 data).....	460
Fig 13.16: (See Fig 10.8; recap): Quality Problems Traced to Vendors (2008-2018).....	462
Fig 13.17: Biopharma Business and Marketing Plans, 2019	464
Fig 13.18: Biopharma Business and Marketing Plans, 2010-2019	466
Fig 13.19A: Top New Technologies or New Product Development Areas	468
Fig 13.19B: Top New Technologies or New Product Development Areas	469
Fig 13.20: Plans for Launching Significant, Truly Novel Bioprocessing Advances (2017 data)	472
Fig 13.21: R&D Spending/Budgets for New Products/Services, 2019	473
Fig 13.22: Areas Where Training is Considered as Needed; 2010 – 2019.....	475
Fig 13.23: Client Demands of Vendors, Service and Support, 2012 - 2019	477
Fig 13.24: Vendors Views of Financial (Sales) Outlook for Next Year, 2011-2019.....	479
Fig 13.25: Average CMOs Service Price Shifts in 2019	480
Fig 13.26: CMOs Service Price Shifts in 2019, Distribution	481

TABLES

Table 0.1 Areas of Biopharmaceutical Manufacturing Operations.....	9
Table 1.1 Recently Announced CMO SUS-based Commercial Scale Expansions & New Facilities.....	23
Table 1.2 FDA Biopharmaceutical Approvals, 2018.....	35
Table 1.3 Number of Biopharmaceutical Products in U.S. and European Markets*	38
Table 1.4 Summary of Worldwide Biopharmaceutical Revenue Growth by Product Class, 2007 and 2018	45
Table 2.1 Total and CMO Facilities Bioprocessing Capacity Scales.....	54
Table 2.2 Regional Distribution of Bioprocessing and CMO Facilities, Total & Average Capacity	57
Table 2.3 Major US W. European Bioprocessing CMOs, # Facilities and Estimated Capacity*	60
Table 2.4 Some Recently Announced CMO SUS-based Commercial Scale Expansions & New Facilities	63
Table 2.5 Constructs and Contracts for Manufacturing	77
Table 2.6 Recent M&A activities	81
Table 2.7 Service offerings and value chains of selected CDMOs.....	83
Table 3.1 Areas of Significant Projected Budget Percentage Increases for Biomanufacturing, 2019 and Past Years	100

Table 4.1	Western European Biomanufacturers' Average Capacity Utilization	153
Table 4.2	U.S. Biomanufacturers' Average Capacity Utilization	153
Table 4.3	Leading Biopharma Company Capacity	159
Table 4.4	Compound Annual Change in Mab Titer, 2008-2019	167
Table 5.1	Severe or Significant Capacity Constraints, by Stage of Production, 2009-2019 ...	176
Table 5.2	Severe and Significant Capacity Constraints Today, U.S. vs. W. Europe, 2010-2019	182
Table 6.1	Western European Biomanufacturers' Five-Year Projected Increases	221
Table 6.2	U.S. Biomanufacturers' Five-Year Projected Increases	221
Table 7.1	Respondents Reporting No Outsourced Production (i.e., all in-house manufacturing), 2009-2019	229
Table 7.2	Respondents Outsourcing up to 50% of Production, Mammalian and Microbial Systems, 2009-2019	229
Table 7.3	Respondents Outsourcing Over 50% of Production, Mammalian and Microbial Cell Systems, 2009-2019	230
Table 7.4	Plant and Insect Cells, 2015-2019	232
Table 7.5	Percent of U.S.-based Respondents Indicating Country as a "Strong Likelihood" or "Likelihood" as Outsourcing Destination, 2009-2019	270
Table 7.6	Percent of European-based Respondents Indicating Country as a "Strong Likelihood" or "Likelihood" as Outsourcing Destination, 2011-2019	274
Table 9.1	Percent experiencing "Serious" or "Some" capacity problems due to downstream processing 2008-2019	345
Table 9.2	Percent U.S. vs. Western Europe facilities experiencing "Serious" capacity problems due to downstream processing, 2009-2019	345
Table 9.3	Percent U.S. vs. Western Europe facilities not expecting to see bottlenecks due to downstream processing, 2008-2018	346
Table 9.4	Upstream Production Titer vs. Max Capacity, 2019 Data	355
Table 13.1	Selected "Other" New Technology Areas in Development	470
Table 13.2	Average Vendor Sales and Technical Training Days, 2011 – 2013, 2019	473

METHODOLOGY

This report is the 16th in our annual evaluations of the state of the biopharmaceutical manufacturing industry. The strength of this study's methodology remains in its breadth of coverage, which yields a composite view from the respondents closest to the industry. This year, BioPlan Associates, Inc. surveyed 221 qualified and responsible individuals at biopharmaceutical manufacturers and contract manufacturing organizations in 24 countries; plus 120 industry vendors and direct suppliers of materials, services and equipment to this industry segment. Using a web-based survey tool, we obtained and evaluated information including regarding respondents' current capacity, production, novel technology adoption, human resources, quality, and outsourcing issues. We also assessed respondents' projected reasons for bottlenecks, and their perception of how these bottlenecks might be resolved.

We continue to provide additional in-depth analysis of specific issues affecting the industry, including monographs in Chapter 2. These monographs cover the events and trends that will shape biopharmaceutical manufacturing over the next five years. We also have included this year a chapter on Continuous Bioprocessing. Over the past few years, advances in technologies, expression systems, and single-use applications have increasingly made this segment an area of interest for innovation.

To ensure comprehensive global coverage, we partnered with world-wide organizations to ensure the most accurate overview of the worldwide biopharmaceutical industry. Our industry partners are cited in our acknowledgments section. In addition, to support this coverage, we also include acknowledgment of our media partners, whose assistance enabled us to reach the many high quality of respondents required in this quantitative analysis.

Further information on methodology, breakouts on specific segments, and data from earlier surveys may be requested by contacting us at the address below.

Eric S. Langer
President
BioPlan Associates, Inc.
2275 Research Blvd., Suite 500
Rockville, MD 20850
301-921-5979
elanger@bioplanassociates.com
www.bioplanassociates.com

CHAPTER 0: DEMOGRAPHICS

INTRODUCTION

Survey respondents included diverse biopharmaceutical senior managers, executives and scientists covering a spectrum involved in biopharmaceutical development and manufacturing, including those within CMOs. As reported below, nearly 90% of respondents had VP, CEO or Director job titles. In addition, in Chapter 13, we separately present responses from bioprocessing suppliers and vendors. As in previous years, responses are from companies of all sizes and types. Respondents have a broad range of responsibilities, but all respondents had to qualify as involved with bioprocessing/manufacturing in some way.

This is an international project done annually, with this now the 16th year edition. We solicit and receive survey responses from individuals at organizations around the world. This year includes input from individuals based in 24 countries.

The diversity of survey respondents supports providing a comprehensive view of the industry from those most involved in managing biopharmaceutical manufacturing activities worldwide. Resulting survey data offer a means for understanding the industry and its future course. The breakdown of results by organization class, such as into CMOs vs. biotherapeutic manufacturers, provides further insights into these two major segments of the industry. These two types of organizations have different business drivers, risk profiles, costs of capital, etc.

0-1 RESPONDENTS' AREA OF INVOLVEMENT

Of the 221 biopharmaceutical manufacturers and contract manufacturing organizations responding to this year's survey, 27.2% were primarily involved in *"Process development for biopharmaceutical manufacturing"*, up from 27.0% in 2018 and 25.6% in 2017; and 26.7% were involved in *"Large-scale cell culture production for therapeutics"*, an increase from 23.4% in 2018 and 25.1% in 2017. There was a sharp decrease to 10.9% for this year for those involved in *"Scale-up (or clinical-scale) production for biopharmaceuticals PRIMARILY"*, compared with 15.8% in 2018 and 14.1% in 2017. But overall, the general pattern of type of organization of those surveyed did not change.


Respondents involved with *"Large-scale contract manufacturing (CMO) for biopharmaceuticals"* increased to 10.4% from 5.4% in 2018. *"Large-scale microbial fermentation for therapeutics"* dropped from 5.9% in 2018 to 4.5%, closer to the 4.8% reported in 2017. *"Vaccine production"* was 9.1%, virtually unchanged from 9.0% in 2018, which was a slight uptick from 8.4% in 2017. *"Other large-scale biopharmaceutical manufacturing"* accounted for 7.2%, the same percentage as in 2018, which was a slight increase from 7.0% in 2017. *"Other" contract manufacturing*

(CMO) for biopharmaceuticals" dropped sharply from 4.5% in 2018 to 1.8%, the lowest level reported since 2014 (2.1%). *"Fill/Finish operations"* accounted for 2.3%, a slight increase from 2018 (1.8%), but still much less than 5.4% in 2016.

Overall, the makeup of respondents remains consistent with prior years' surveys. Despite variations, including decreases, in involvement in aspects of biopharmaceutical manufacturing, this year's data continue to fall within the range generally defined by prior years' data reports, with the relative rankings remaining largely unaffected. This year-to-year coherency supports the accuracy of these demographic data.

Fig 0.1: Area of Primary Involvement in Biopharmaceutical Manufacturing, 2010 to 2019

***"In which area of biopharmaceutical manufacturing is your organization currently involved?"
(2010 to 2019)***




0-2 RESPONDENTS QUALIFICATIONS

Respondents were asked about their areas of responsibility, as indicated by job title (Fig. 0.2). Over 89% had a title of “VP, Director, or President/CEO”, a slight decrease from last year’s 92%, but still consistent with the levels since 2014, with an average of about 90% in recent years. This year, 12.2% of respondents were “VPs, Directors or Managers of QA, QC, Validation, or RA”, an increase from 9.9% in 2018 and closer to the 11.0% in 2017, but not as high as 15.8% in 2016. The category “Engineer or Scientist: PD, R&D, and Production” (i.e., without VP/Director/Manager responsibilities) accounted for 10.9% of respondents, a marked increase from 7.7% in 2018, but overall a decrease from 11.0% in 2017.

“Presidents/CEOs” represented 6.3% of respondents, down from 7.2% in 2018 and 5.3% in 2017; and “VPs or Directors of R&D” accounted for 3.2% of respondents, a dramatic decrease from 7.2% in 2018 and less than previous years. The category “VP or Director: Operations” grew substantially to 13.6% in this year’s survey, up from 8.1% in 2018 and 8.8% in 2017. “VPs, Directors or Managers in Process Development” again comprised the largest percentage of respondents at 37.1%, up from 33.8% in 2018 and 36.1% in 2017. Although “VPs, Directors or Managers of Manufacturing and Production” accounted for the next-highest percentage at 16.7%, this was much lower than 26.1% in 2018 and 22.9% in 2017. Combining “VPs, Directors, and Managers in Process Development” with those in Manufacturing and Production, the total is 53.8%, still representing most of the respondents, but less than the 59.9% in 2018. Overall, respondent job titles and levels of responsibility have changed little over the years.

Fig 0.2: Respondents' Job Responsibilities, 2011 – 2019


Which best describes your primary job responsibilities?

0-3 FACILITY LOCATIONS

This year, surveyed respondents were based in 24 countries (Fig. 0.3). Approximately 54% of the respondents were from the United States, with the Northeastern U.S. continuing to make up the largest group at 24.4%, a decrease from 27.9% in 2018 and 28.6% in 2017. Respondents from Western Europe made up just over 23% of the total, an increase from 18.9% in 2018 and closer to the 24% in 2017 and 21.4% in 2016. Asia is well represented, including a dramatic growth from 6.8% in 2018 to 9.0% in India, but a decrease from 8.1% in 2018 to 5.0% in this year's survey in China. Other countries (not covered by reporting of specific countries) continued to make up 4.1% of the respondents. The geographic distribution of respondents is similar to the distribution of bioprocessing facility capacity, discussed in sections below.

Further information about biopharmaceutical manufacturing facilities worldwide is available at the *Top 1000 Global Biopharmaceutical Facilities Index Web site* from BioPlan Associates (www.Top1000Bio.com)


Fig 0.3: Facility Location



We note that there was a slight decrease in U.S. respondents (54%) from 59% in 2018, 55% in 2017 and 61% in 2016 (Fig. 0.4). The percentage of Western European respondents (23.5%) increased somewhat from 18.9% in 2018, closer to the 24% in 2017 and the near constant 20% participation since 2011. This year ROW is represented by 22.2%, a slight increase over 21.6% in 2018 and 20.7% in 2017 and surpassing the peak of 22.0% in 2013.

Fig 0.4: Facility Location, by Region

***Respondents' Facility Location by Region
(Biotherapeutic Developers and CMOs)***



Western Europe respondents include: Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Netherlands, Portugal, Spain, Sweden, Switzerland, United Kingdom, Holland, Hungary, Norway and Turkey.

“Rest of World” respondents include: Canada, Australia, India, China, Singapore, Egypt, Japan, Russia, Estonia, Iceland, Israel, Argentina, Brazil, Bulgaria, Cuba, Korea, Lithuania, New Zealand, Poland, Slovenia, South Africa, Taiwan, Thailand, Malaysia, Iran, Mexico, Albania, Philippines, Vietnam, Pakistan, Chile, Indonesia and Puerto Rico.

0-4 AREAS OF BIOPHARMACEUTICAL MANUFACTURING OPERATIONS

Mammalian Cell culture continues to dominate product development and manufacture, and this is reflected in the survey data. Further, a majority of biopharmaceutical products in the development pipeline and entering the market are mammalian-expressed, including various recombinant monoclonal antibody (mAb) products, with this now including multiple biosimilar versions of many of these mAbs. With the continuing incremental increases in mammalian system titers and yields, and with mammalian culture all that many bioprocessing professionals are now knowledgeable about, many facilities are standardizing using mammalian vs. microbial systems. In some cases, this even includes products that could be manufactured in microbial systems, which are generally cheaper or more productive, but are now often initially manufactured in mammalian systems, if these get the job done, such as to produce pre-clinical or early clinical supplies. Besides mammalian being the dominant platform, but generally more expensive than microbial manufacture, technology development continues using mammalian platforms. Mammalian manufacturing has advantages including being more adaptable to single-use systems manufacturing, besides more bioprocessing professionals now being more familiar with mammalian vs. microbial manufacturing. The state of mammalian and microbial manufacturing is also discussed in other sections below.

Respondents reported involvement in seven categories of expression systems for 2019 (see Table 4.1) and changes over time (see Fig. 0.5). Percentages ranged from 74.2% (*Mammalian Cell Culture*) to 9.1% (*Plant Cells*). This year, we see a continued decrease in facilities using “*Mammalian Cell Culture*”, down to 74.2% from 79.3% in 2018 and 81.1% in 2017. There was also a decrease in “*Microbial Fermentation*” systems to 43.5% from 47.8% in 2018, following a substantial increase from the previous year’s 40.3%. Note: respondents were permitted to select multiple expression systems.

Also observed was a continued decrease in the overall percentage of respondents using “*Yeast*”, from 19.4% in 2017 to 16.7% in 2018 to 12.4% this year. However, following a drop from 9.7% in 2017 to 3.9% in 2018, the use of “*Insect Cells*” rose substantially to 10.0%.

Following a steep increase from 2017 to 2018, “*Microbial Fermentation*” showed a decrease in 2019, from 47.8% to 43.5%. “*Cell Therapy* and *Gene Therapy*”, on the other hand, continued to increase, to 20.6% and 18.7% in 2019, respectively. “*Plant Cells*”, after a slight increase from 2017 to 2018 (2.6% to 3.4%, less than 1% above the 5-year average), jumped to 9.1% in 2019. The industry appears to be slowly increasing the diversity of basic expression systems/platforms in use.


Table 0.1 Areas of Biopharmaceutical Manufacturing Operations

Answer Options	Year 2019	Year 2018
Mammalian Cell Culture	74.2%	79.3%
Microbial Fermentation	43.5%	47.8%
Cell Therapy	20.6%	17.2%
Yeast	12.4%	16.7%
Gene Therapy	18.7%	14.8%
Insect Cells	10.0%	3.9%
Plant Cells	9.1%	3.4%

Fig 0.5: Biopharmaceutical Manufacturing Systems, (2007-2019) Trends

In which of the following does your facility currently have production operations for biopharmaceutical products?

2007- 2019 (Trends)



0-5 PRODUCTION OPERATIONS, PHASE OF DEVELOPMENT


We identified the phases of pipeline development in which respondents' organizations (companies) had products (Fig. 0.6). This year, slightly over half (50.7%) of companies had products at the "*R&D*" stage, a decrease from 53.2% in 2018. This reflects a continued shift in R&D back to the relative 50% level seen in almost all previous years, but is still much lower than the 73.3% reported in 2006. Facilities involved with "*Preclinical*" operations were at 50.7%, a decrease from 55.5% in 2018 and 62.6% in 2017. Note: respondents could indicate multiple phases of development for their facility.

This year respondents reported that 50.2% of facilities have biopharmaceutical products on the market, an increase from 44.5% in 2018 and closer to the 52.5% reported in 2017. Those working with "*Phase I*" development saw a drop from 61.1% in 2017 to 53.7% in 2018 to 51.6% in 2019. Facilities working with "*Phase III*" development had a slight drop from 49.1% in 2018 to 48.4% in 2019, following a 10% drop from 2017 that suggested a tightening of development pipelines. Hopefully, developers are making better choices regarding their product candidates, in terms of failing faster and/or less frequently.

The respondent facility phase of development data continue to have small annual fluctuations as the industry continues its overall maturation, with most respondents now employed by companies with revenue streams from marketed biologics. 2009 has been widely noted as the year the biopharmaceutical industry finally, as a whole, turned a profit. Overall, the employers of the surveyed biopharmaceutical manufacturing-related professionals are rather evenly distributed over the pipeline spectrum from pre-clinical through commercial manufacturing, with each phase being worked on by approximately 50% of survey respondent organizations.

Fig 0.6: Phase of Development of Surveyed Respondents, 2006-2019


In which phases of development does your organization currently have biopharmaceutical products?
2006-2019



Western European respondents continued to indicate higher involvement by their companies with “*Preclinical*” products at 57.7%, while U.S. companies indicated lower involvement at 53.4% (compared to 58.5% vs. 54.7% in 2018), respectively. This is somewhat unexpected, in the context that overall the U.S. has more biopharmaceutical R&D facilities compared to Europe. This followed a reversal in 2017 from the previous year, when Western European companies showed lower involvement than U.S. companies (55.3% vs. 66.1%).

This year shows a greater difference between U.S. and Western European facilities in terms of *Phase I* clinical trials, at 50.8% vs. 57.7%, respectively. In 2018, the percentages were much closer at 53.1% vs. 53.7%, and in 2017, those reporting Phase I clinical trials in the U.S. far outnumbered those in Western Europe at 65.1% vs. 55.3%, respectively. Also seen this year is an increase in *Phase III* clinical trials in Western Europe at 50.0% (vs. 45.8% for the U.S.), compared to 2018 (39.0% vs. 51.6% for the U.S.), following a large decrease from 2017 (55.3% vs. 60.6% for the U.S.).

Fig 0.7: Phase of Development of Surveyed Respondents (U.S. vs. Western Europe)




0-6 EMPLOYEES AT FACILITY

To evaluate issues such as capacity, single-use systems usage and other factors, we asked respondents to report the estimated number of staff within their own facility, and within their total organization (Fig. 0.8).

The largest percentage of respondents continued to be at facilities with 100-499 staff members. Continuing a prior trend, the largest share of respondents, 36.5%, were from parent organizations with *greater than 5,000* employees, most of whom, as expected, were presumably employed by Big (Bio)Pharma companies.

These data reflect the relative distribution of biopharmaceutical manufacturing-related professionals' employment within the biopharmaceutical industry. This includes the increasing involvement and even dominance of larger companies in biopharmaceutical R&D and products marketing. And with most Big Pharma type companies and larger generic drug and foreign pharmaceutical companies continuing to move into biopharmaceuticals, the dominance of large companies as employers of biopharmaceutical manufacturing professionals will likely continue to incrementally increase.

Fig 0.8: Distribution of Employees at Facility, and Organization




0-7 BATCHES RUN AT FACILITY PER YEAR

To continue our evaluation of issues such as batch failure rates, and to ensure we are capturing organizations involved in significant manufacturing processes at various scales of manufacture, we again this year asked for estimates of the number of batches or production runs at the respondent's facility (not the organization) over the past 12 months (Fig. 0.9).

We found that for “*Clinical Scale*” manufacturing, more than half of the facilities reported producing between 1 and 20 batches per year (57.3%), a more than 6% increase over 53.8% in 2018. At “*Commercial Scale*”, only 7.7% reported producing over 150 batches per year, down from 8.7% in 2018 and 11.7% in 2017. The level of commercial scale manufacturing between 0-70 batches per year was 71.4%, down from 75.4% in 2018 and 75.9% in 2017.

This year, we saw decreases in runs of 0-10 batches compared to 2018 levels at both “*Clinical Scale*” and “*Commercial Scale*”, from 50.4% to 43.9% and from 47.6% to 34.3%, respectively.

Fig 0.9: Distribution of Total Batches Run at Facility Last Year, by Scale of Production

0-8 SINGLE-USE BIOREACTOR CAPACITY IN USE AT SITE


To follow the trend of single-use bioreactor capacity within the industry, we asked respondents again this year about the largest single-use bioreactor capacity in use at their site, in liters (Fig. 0.10).

The largest increase from 2018 was 500 L capacity, jumping from 11.9% to 18.3% in this year's survey. The largest total percentage indicated 1,000 L, at 18.7%, an increase from 16.9% in 2018 continuing to indicate likely late-stage clinical or even commercial manufacturing facilities. Behind 500 L and 1,000 L, the next highest percentage was again for 2,000 L, at 16.9%, an increase from 14.2% in 2018.

More than one-third of respondents reported $\geq 1,000$ L single-use bioreactors at their facilities, i.e., working at large scale by single-use standards, an 18% increase from 2018 (33.4% vs. 39.7%). As expected, few respondent facilities had single-use bioreactors with greater than 2,000 L capacity, although, there was a significant increase over 2018, from 2.3% to 4.1%.

Fig 0.10: Distribution of Largest SINGLE-USE Bioreactor Capacity

What is the LARGEST single-use bioreactor capacity in use at your site? (n=219)



0-9 STAINLESS STEEL BIOREACTOR CAPACITY IN USE AT SITE


We continued to ask respondents again this year what was the capacity of the largest stainless-steel bioreactor at their facility (Fig. 0.11).

In 2019, the largest reported average size of on-site stainless steel bioreactors was 4,125 L, compared with an average of about 659 L for single-use bioreactors at survey respondents' sites.

The top three percentages reported were for 100–499 L, 2,000–4,999 L, and 10,000–19,999 L, each at 12.8%, compared to 2018, the largest percentages were for 2,000–4,999 L at 15.5%, followed by <10–99 L at 12.3%, and 10,000–19,999 L at 11.0%. The proportion with largest stainless steel bioreactors on-site with less than 1,000 L capacity increased from 35.9% in 2018 to 38.0%.

Comparing the data reported for the largest in-house single-use vs. stainless steel bioreactors, over one-third (35.7%) of facilities with stainless steel have $\geq 2,000$ L bioreactors vs. 21.0% for single-use (compared to 37.5% and 16.5%, respectively, in 2018). This indicates increasing adoption of single-use bioreactors for entry-level single-use commercial manufacturing mostly involving use of 2,000 L single-use bioreactors.

Fig 0.11: Distribution of Largest STAINLESS Bioreactor Capacity



CHAPTER 1: INTRODUCTION AND DISCUSSION

1-1 INTRODUCTION: THE PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRIES

The pharmaceutical and its biopharmaceutical industry subset remain active, profitable and growing economic technology- and science-based activities and industries. This is despite about a decade ago having successfully survived the worldwide economic problems; the industry increasingly being targeted for criticism for excessively high prices; and biosimilars/biogenerics increasingly posing a threat to established products. There are estimated to be well over 10,000 therapeutics in R&D, both drugs (chemically-derived pharmaceuticals) and biopharmaceuticals (biotechnology- or living organism-derived pharmaceuticals), with nearly 40,000 ongoing or recently reported clinical trials. Among these, $\geq 40\%$ or likely soon approaching 5,000 candidate products in R&D are biopharmaceutical products. A significant portion, now $> 1,700$, products in the development pipeline, are follow-on biopharmaceuticals, mostly biosimilars and biobetters in major markets and a large number of biogenerics in lesser- and non-regulated developing countries and international commerce.

This 16th annual version of this publication continues to use consistent definitions for “biopharmaceutical” and “bioprocessing.” “Biopharmaceutical” refers to pharmaceuticals, generally therapeutics, manufactured from and/or by living organisms; and the biotechnology processing involved is “bioprocessing.” Source organisms are generally microbial, including nearly all sources for recombinant biopharmaceutical products, but can also come from other living organisms, e.g., Factor VIII or stem cells derived from pooled human blood/plasma. Biopharmaceuticals do not include pharmaceuticals that are synthetically manufactured or can be considered small molecule drugs. Generally, if a drug substance’s (active agent’s) structure can be represented or drawn without having to resort to use of names or symbols for component parts, such as amino acids with proteins and many fermentation products, including many antibiotics, it is a small molecule drug. Similarly, synthetic and purely semi-synthetic substances (e.g., purified enzymes used to drive chemical reactions) are not considered biopharmaceuticals.

The large number of biosimilars and biobetters in development indicate the maturation of the biopharmaceutical industry, as its current major blockbuster products and established platform technologies start to go off-patent. This represents a considerable shift in the biopharmaceuticals’ product mix. Major changes brought by follow-on biopharmaceuticals include a rapidly increasing number of marketed biopharmaceutical products, particularly compared to as short as 5 or more years ago, and a number of new players entering the biopharmaceutical industry. The large proportion of industry R&D and manufacturing being devoted to follow-ons also contributes to basic shift in the pharmaceutical industry and

healthcare from small molecule drugs to biopharmaceuticals with increasing generic drug sector-like competition. This will accelerate in the U.S. market, the largest biopharmaceuticals' market, once FDA implements regulations for "interchangeable" biosimilars.

Until relatively recently, pharmaceutical companies of all sizes, particularly the Big Pharma-type companies that now dominate biopharmaceutical R&D, have often continued to cut back on expenses as much as possible and consolidate R&D and companies, with the resulting companies often ending up concentrating on developing fewer products. Most every major merger/acquisition seems to include the acquirer up-front claiming the new company will have a larger and healthier pipeline products, increased capacity and expertise, etc. However, it also seems that this rarely happens, with much merger/acquisition activity apparently more to distract stockholders and boost appearances and through this stock value, while the new bigger post-merger/acquisition companies almost invariably soon consolidate and cut-back their combined R&D pipelines, close facilities, outsource more tasks previously considered better done in-house, etc. Luckily, this trend is slowing, although this could just be from there being fewer big-time players to allow much additional merging and purging among the largest companies. But in terms of biopharmaceuticals, any decreases in existing player company R&D is likely being more than counter-balanced by both other established pharmaceutical and new companies worldwide moving into biopharmaceuticals. This increasingly includes a large number of new entrants moving into the biosimilar/biogenerics, cellular and gene therapies areas. As discussed below, the biopharmaceuticals industry keeps on expanding at a rather steady pace.

But even if there were significant pipeline shrinkage, this may not be a negative trend. This could simply reflect the industry doing a better job in eliminating fewer promising candidates before they enter or earlier in clinical trials. This "failing faster," i.e., earlier in development, is generally much less costly and disruptive than products failing later in development. If the industry is doing a better job of weeding out poor candidate products earlier, the industry may be on track for increased future success and increased productivity and profits, with fewer costly late-stage failures and a higher percentage of pipeline products making it to the market.

Along with more R&D and marketed products, the pharmaceutical R&D pipeline and industry are becoming increasingly dependent on biopharmaceuticals. Besides profits, with biopharmaceuticals generally providing higher profits, this includes public image. Big Pharma companies, led by PhRMA, have been rather successful in their decade-plus efforts to co-opt the terms "biopharmaceuticals" and "biopharma," particularly in popular use, to apply to themselves and include all pharmaceuticals, particularly all those that are innovative or otherwise have a positive public image [see Rader, R.A., "(Re)Defining Biopharmaceutical" *Nature Biotechnology*, July 2008, 26(7), p. 743-751]. Thus, it is now often a rarity when the terms "biopharma" or "biopharmaceutical" refer to biopharmaceuticals (biotechnology-manufactured) vs. just innovative or even all pharmaceuticals. PhRMA and many others now use the term "biopharmaceutical" with much consistency, but not to refer to actual biopharmaceuticals. The greater pharmaceutical industry and its hangers-on, including stock analysts and the trade press, often variably use the term with little consistency, and rarely ever explain the term's use/scope. Readers should use caution and inspect any definitions or scope notes provided where information about the "biopharmaceutical" or "biopharma" industry is being discussed. Many of those who use the term now are not using it with any explicit linkage to biotechnology (with biopharmaceuticals derived by biotech methods, i.e., manufactured using live organisms).

Biopharmaceutical products are being developed by an ever-increasing cross section of the pharmaceutical industry, including Big Pharma, generic drug, and foreign companies, with many of these new entrants entering the field by developing biosimilars. These newer types of entrants, along with smaller biotech business model-type biopharmaceutical developers

which have been the traditional source for most innovative biopharmaceuticals before licensing by larger companies, are continuing to expand the global biologics pipeline. Biosimilars are bringing in many new biopharmaceutical developers and manufacturing facilities. This includes new entrants based in China, India and other developing countries increasingly entering biopharmaceutical R&D. An increasing number and percentage of new pharmaceuticals entering the market will be biopharmaceuticals vs. small molecule drugs; and these will originate from more diverse sources. Combine this with biopharmaceuticals (vs. drugs) generally costing much more and providing higher profit margins, and the pharmaceutical industry will increasingly be dependent on biopharmaceuticals for profits, innovation, and its basic survival.

As biopharmaceuticals become an even more important part of the pharmaceutical industry and with many new players entering the field, as our annual survey shows, most every current manufacturing facility is expanding its bioprocessing capacity in one way or another. Not only must bioprocessing output expand to handle manufacture of an increasing number of approved products and higher volumes as markets for many current products further expand, e.g., with approvals for new indications and growth in international markets, the industry must also be capable of handling novel bioprocessing and biopharmaceuticals. The industry must continue to develop manufacturing capacity for a wide range of new(er) product types, e.g. cellular therapies, gene therapies, ADCs, stripped-down antibodies, RNAi, live microbes as therapeutics, etc., with ever more diverse bioprocessing requirements.

The strategic importance of biopharmaceutical manufacturing and manufacturing capacity is increasing, and understanding the markets for biopharmaceuticals and bioprocessing technologies, industry capacity and services is becoming ever more important to those in the industry. Planning and decision-making concerning the manufacture of biopharmaceuticals are becoming more complex as companies continue, whether spurred by habit, actual need or for the sake of investors, to implement cost-saving efforts periodically or even constantly. This can include cutting back on the number of products in their development pipelines or outsourcing of support and even critical tasks.

Effective planning within the (bio)pharmaceutical and bioprocessing markets is required to avoid problems later. This ideally involves a high level of leadership, partnership, information sharing, and communication between manufacturers, CMOs and bioprocessing technology and equipment suppliers as they develop and adopt new manufacturing technologies, devices and capacity to keep pace with industry needs. Strategic production decisions must be based on solid bioprocessing and sales projection data, combined with a broad understanding of trends and effective benchmarking of capacity and production issues. This study provides an on-going evaluation of the vital manufacturing trends shaping this industry, and is designed to help keep those in the industry aware of the internal industry and external trends and issues affecting biopharmaceutical decision-making.

Many companies, even more affluent and established ones, are continuing to aggressively look for opportunities to cut costs and increase efficiency, with this continuing to benefit contract manufacturing and research organizations (CMOs and CROs). But many other companies are increasingly confident and are pushing ahead investing in in-house resources and doing full development and commercial manufacturing in-house. Prior rather common periodic severe arbitrary cuts in staff and divestment of facilities have largely ended, but this may simply reflect already reaching the limits of eliminating in-house expertise and facilities. Many, particularly the largest biopharmaceutical companies.

Among many of the very largest companies, including Big Pharma, we still see cycles of short-term on-paper/theoretical profits and claims of synergies driving decisions and related investor concerns, with companies needing to distract investors from long-term problems, such as fewer

products making it to the market, lower R&D productivity and innovation, payers resisting high-cost product coverage, etc., through habitual company merging and purging. This commonly includes merging or acquiring smaller (or just as large) companies and then consolidating, with staff lay-offs, closing of facilities, abandonment of products in the combined company pipelines, and other cutbacks. While involved companies typically claim synergies, that their resulting pipelines will be better, that there will be more innovation, etc., this rarely happens as projected, but the new larger company lives on, with investors happy for the moment. But as the consequences of mergers and acquisitions and related consolidations and shedding of corporate resources and staff catch-up with the acquiring companies, they are then forced again to go through merge-purge cycles just to survive and please or distract investors. Many in industry seemingly have come to expect such consolidations as normal, how the mainstream major market-based pharmaceutical industry works, how these companies add to their valuations, etc.

A large portion of biopharmaceuticals coming to market involves therapies for diseases often ignored or currently untreatable, making them particularly welcome and needed. In recent years, this includes many products for orphan indications, with FDA and other regulatory agencies proactively supporting this. This includes FDA granting transferrable vouchers now selling for up to several \$100 million each that grant the holder more rapid evaluation of product applications.

While much action in major market, affluent countries involves innovative orphan therapeutics development, non-innovative biogenerics directed to lesser- and non-regulated international markets is where the growth is in developing countries. These markets are also but much less involved with development of biosimilars (with biosimilar approvals requiring extensive comparative clinical and analytical testing often not performed with biogenerics; generally restricted to more regulated markets). Many new entrant foreign companies of all sizes and types are developing biosimilars and/or biogenerics and plan to use these to establish themselves in the biopharmaceutical industry. This is resulting in a significant increase in the number of biopharmaceutical players and manufacturing facilities, and as noted below, an increase in single-use-based manufacturing facilities.

Most large commercial biopharmaceutical manufacturing capacity expansions continue to involve building fixed stainless steel bioreactor-based bioprocessing systems, with commercial manufacturing using single-use systems just getting started. In the extreme, large stainless steel facilities coming online are exemplified by Samsung and Celltrion in S. Korea. Celltrion has reported plans to expand from its already super-size 140,000 L to 330,000 L capacity. This continued use of stainless steel at the largest scales is in contrast with production of supplies for R&D and clinical testing, which is now dominated by use of single-use/ disposable bioreactor-based systems, with this requiring much smaller bioreactors, facilities and infrastructure investment. About the only area of pre-commercial manufacturing not substantively using single-use systems at least is microbial fermentation, which generally continues to remain unchanged. Microbial fermentation continues to use much more extreme conditions (mixing, higher temperatures, etc.) than mammalian cell culture, with this restricting use of single-use systems. Overall, we are early in what will likely be a significant trend of developers adopting single-use systems for commercial product manufacturing, often involved scaling-out with multiple $\leq 2,000$ L bioreactor-based process lines in parallel.

Recently there has been a significant increase in new single-use commercial-scale manufacturing facilities under construction and coming online. A good portion of these facilities are for biosimilars manufacture; and most are “flexible,” able to be adapted for manufacture of multiple products (vs. being single product dedicated). These new single-use commercial manufacturing facilities include modular facilities, including the first good-sized modular

For Ordering Information on the Full Report, contact

BioPlan Associates, Inc.

301-921-5979

www.bioplanassociates.com/16th





SIXTEENTH ANNUAL

Report and Survey of Biopharmaceutical Manufacturing Capacity and Production

Another report in the BioPlan Associates, Inc.'s biopharmaceutical series:

- Advances in Biopharmaceutical Technology in China, 2nd Ed., 2018, Soc. Ind. Microbiol, Biotech
- Top 60 Biopharmaceutical Organizations in China, 2nd Ed., 2018
- Quick Guide to Clinical Trials, 2nd Ed., 2017
- Biosimilars Pipeline Database - <http://www.biosimilarspipeline.com/index.html>
- Top 1000 Global Biomanufacturing Facilities - Global analysis and ranking of capacity, employment and pipelines, www.top1000bio.com
- Biopharmaceutical Expression Systems and Genetic Engineering Technologies
- Advances in Biopharmaceutical Manufacturing and Scale-up Production, Amer. Soc. Micro.
- Biopharmaceutical Products in the U.S. and European Markets, 8th Ed.
- Advances in Biopharmaceutical Technology in India
- Top 60 Biopharmaceutical Organizations in India
- Quick Guide to Biotechnology in the Middle East
- Quick Guide to Biofuels

The 16th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production is the most recent study of biotherapeutic developers and contract manufacturing organizations' current and projected future capacity and production. The survey includes responses from **221 responsible individuals** at biopharmaceutical manufacturers and contract manufacturing organizations from **24 countries**. The survey methodology includes input from an additional **120 direct suppliers** of raw materials, services, and equipment to this industry. In addition to current capacity issues, this study covers downstream processing problems, new technologies, expression systems, quality initiatives, human resources and training needs of biopharmaceutical manufacturers, growth rates of suppliers to this industry, and many other areas.

Copyright © 2019 by BioPlan Associates, Inc.

April 2019

ISBN 978-1-934106-36-5

